Desmopressin Evidence Guide
Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and hemostasis in mild hemophilia A/von Willebrand disease type I - a broad indication profile reflecting 40+ years of clinical evidence. Its selectivity for V2 receptors over V1 receptors (versus natural vasopressin) makes it the preferred ADH analog for antidiuretic applications. A highly validated, multi-indication peptide drug.
Our Take
Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and hemostasis in mild hemophilia A/von Willebrand disease type I - a broad indication profile reflecting 40+ years of clinical evidence. Its selectivity for V2 receptors over V1 receptors (versus natural vasopressin) makes it the preferred ADH analog for antidiuretic applications. A highly validated, multi-indication peptide drug.
- Evidence context
- Central diabetes insipidus, nocturnal enuresis, hemostasis in mild hemophilia A/vWD type I, ADH receptor research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 0.1-0.4mcg IV/subcutaneous or 0.1mg oral (DI); 300mcg intranasal single dose (hemostasis)
Benefits and Evidence
- Central Diabetes Insipidus: Level A, includes human evidence - Gold standard treatment for central diabetes insipidus. Effectively reduces urine output from >10 L/day to normal volumes and controls thirst and polydipsia.
- Nocturnal Enuresis: Level A, includes human evidence - Meta-analyses show significant reduction in wet nights. Complete dryness achieved in approximately 25-30% of children, with significant improvement in many more.
- Hemophilia A / vWD Bleeding: Level A, includes human evidence - Raises factor VIII and vWF levels 2-5 fold within 30-60 minutes. Effective for prevention and treatment of bleeding in mild hemophilia A and type 1 von Willebrand disease.
- Hyponatremia Risk: Level A, includes human evidence - Water retention can cause hyponatremia, potentially leading to seizures. Risk is higher in elderly patients and children. Fluid restriction is essential.
Side Effects and Warnings
- Headache
- Nasal congestion (intranasal)
- Nausea
- Abdominal cramps
- Facial flushing
- Hyponatremia
- Hyponatremia/water intoxication - restrict fluid intake; monitor serum sodium
- Contraindicated in habitual polydipsia
Research Dosage References
- <strong>Intranasal spray</strong> - 10-40 mcg - Once or twice daily - For diabetes insipidus. Typical dose 10-20 mcg at bedtime, with optional morning dose. Titrate based on urine output.
- <strong>Oral tablet</strong> - 0.1-0.4 mg - Two to three times daily - For diabetes insipidus. Start at 0.05 mg twice daily and titrate. Oral bioavailability ~5% of intranasal.
- <strong>Sublingual (melt)</strong> - 60-240 mcg - Once at bedtime - For nocturnal enuresis. Place under tongue. Restrict fluid intake from 1 hour before to 8 hours after dosing.
Mechanism of Action
Desmopressin acts primarily through selective V2 receptor agonism: 1. V2 receptor selectivity: >3000-fold selectivity for V2 over V1a receptors, providing antidiuretic effect without significant vasoconstriction. 2. Aquaporin-2 insertion: V2 receptor activation in renal collecting duct principal cells triggers cAMP cascade, leading to translocation and insertion of aquaporin-2 water channels into the apical membrane. 3. Factor VIII and vWF release: Stimulates release of von Willebrand factor (vWF) and factor VIII from endothelial Weibel-Palade bodies, useful in mild hemophilia A and type 1 von Willebrand disease. 4. Prolonged duration: Resistance to enzymatic degradation (due to deamination) extends half-life to 2-4 hours, allowing practical dosing schedules.
Legal Status
FDA-approved for central diabetes insipidus, primary nocturnal enuresis, hemophilia A, and type 1 von Willebrand disease. Multiple formulations available by prescription. Marketed by various manufacturers including Ferring.
Primary Sources
- Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev, 2002.
- DDAVP in the treatment of central diabetes insipidus. J Intern Med, 2004.
- Desmopressin for the treatment of bleeding disorders. Haemophilia, 2008.
Quick Answers
Where is the strongest evidence for Desmopressin?
Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and hemostasis in mild hemophilia A/von Willebrand disease type I - a broad indication profile reflecting 40+ years of clinical evidence. Its selectivity for V2 receptors over V1 receptors (versus natural vasopressin) makes it the preferred ADH analog for antidiuretic applications. A highly validated, multi-indication peptide drug. Evidence context: Central diabetes insipidus, nocturnal enuresis, hemostasis in mild hemophilia A/vWD type I, ADH receptor research.
What are the main side effects of Desmopressin?
Desmopressin side effects and warning signals include Headache, Nasal congestion (intranasal), Nausea, Abdominal cramps, and Facial flushing.
What evidence level is Desmopressin?
Desmopressin is rated Level A; the listed research status is FDA Approved.